- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
- Profile
- Financials
Verve Therapeutics (VERV)
Company Profile
| Quarter (USD) | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 101.33 mm | 101.33 mm | 101.33 mm | 101.33 mm | 101.33 mm | 101.33 mm |
| Cash burn (monthly) | 25.34 mm | 3.97 mm | 12.21 mm | 17.37 mm | 9.28 mm | 11.87 mm |
| Cash used (since last report) | 206.03 mm | 32.29 mm | 99.31 mm | 141.26 mm | 75.48 mm | 96.54 mm |
| Cash remaining | -104.70 mm | 69.04 mm | 2.02 mm | -39.94 mm | 25.85 mm | 4.79 mm |
| Runway (months of cash) | -4.1 | 17.4 | 0.2 | -2.3 | 2.8 | 0.4 |
| 13F holders | Current |
|---|---|
| Total holders | 171 |
| Opened positions | 23 |
| Closed positions | 29 |
| Increased positions | 63 |
| Reduced positions | 54 |
| 13F shares | Current |
|---|---|
| Total value | 426.25 bn |
| Total shares | 102.30 mm |
| Total puts | 157.30 k |
| Total calls | 67.37 k |
| Total put/call ratio | 2.3 |
| Largest owners | Shares | Value |
|---|---|---|
| GOOG Alphabet | 12.35 mm | $69.65 bn |
| GV 2017 | 12.35 mm | $145.60 mm |
| BlackRock | 7.53 mm | $42.44 bn |
| Biotechnology Value Fund L P | 6.90 mm | $31.07 mm |
| BVF | 6.90 mm | $38.94 bn |
| Vanguard | 4.01 mm | $22.60 bn |
| Casdin Capital | 4.00 mm | $22.54 bn |
| Millennium Management | 3.92 mm | $22.10 bn |
| Schonfeld Strategic Advisors | 3.79 mm | $21.37 bn |
| STT State Street | 3.24 mm | $18.25 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 25 Jul 25 | MacLean Michael F | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.73 | 42,200 | 241.81 k | 0 |
| 25 Jul 25 | MacLean Michael F | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.02 | 136,139 | 683.42 k | 0 |
| 25 Jul 25 | Krishna Yeshwant | Common Stock | Dispose U | Yes | No | 0 | 1,800,000 | 0.00 | 0 | |
| 25 Jul 25 | Krishna Yeshwant | Common Stock | Dispose U | Yes | No | 0 | 4,260,047 | 0.00 | 0 | |
| 25 Jul 25 | Krishna Yeshwant | Common Stock | Dispose U | Yes | No | 0 | 6,108,442 | 0.00 | 0 | |
| 25 Jul 25 | Krishna Yeshwant | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.73 | 42,200 | 241.81 k | 0 |
| 25 Jul 25 | Krishna Yeshwant | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.02 | 136,139 | 683.42 k | 0 |
| 25 Jul 25 | Allison Dorval | Common Stock | Dispose U | No | No | 0 | 13,280 | 0.00 | 0 | |
| 25 Jul 25 | Allison Dorval | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 12.75 | 180,000 | 2.30 mm | 0 |
| 25 Jul 25 | Allison Dorval | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 1,875 | 0.00 | 0 |